clindamycin
150mg/mL injection, 150mg oral capsule

© Department for Health and Ageing, Government of South Australia. All rights reserved.

Note:
This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient’s medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary,
- Advising consumers of their choice and ensuring informed consent is obtained,
- Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements

Synonyms
Clindamycin phosphate, Clindamycin hydrochloride

Dose and Indications

Infection due to susceptible organisms

Intravenous, Oral

Infectious Disease consultation is usually required prior to commencing therapy, refer to local anti-microbial policy

5 to 7.5mg/kg/dose

<table>
<thead>
<tr>
<th>Corrected Age (weeks)</th>
<th>Postnatal age (days)</th>
<th>Frequency (hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>[Gestational Age PLUS Postnatal Age]</td>
<td>≤ 28</td>
<td>every 12 hours</td>
</tr>
<tr>
<td>&lt;30</td>
<td>&gt; 28</td>
<td>every 8 hours</td>
</tr>
<tr>
<td>30 to 36</td>
<td>≤ 14</td>
<td>every 12 hours</td>
</tr>
<tr>
<td></td>
<td>&gt; 14</td>
<td>every 8 hours</td>
</tr>
<tr>
<td>37 to 44</td>
<td>≤ 7</td>
<td>every 12 hours</td>
</tr>
<tr>
<td></td>
<td>&gt; 7</td>
<td>every 8 hours</td>
</tr>
</tbody>
</table>

Length of treatment should be guided by pathology and clinical picture; however in proven sepsis treatment should continue for a minimum of 7 days.
clindamycin
150mg/mL injection, 150mg oral capsule

Preparation and Administration

**Intravenous**
Dilute 1mL of clindamycin 150mg/mL with 14mL compatible fluid (total volume 15mL). The resulting solution contains clindamycin 10mg/mL solution.

<table>
<thead>
<tr>
<th>Dose</th>
<th>2.5mg</th>
<th>5mg</th>
<th>7.5mg</th>
<th>10mg</th>
<th>12.5mg</th>
<th>15mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>0.25mL</td>
<td>0.5mL</td>
<td>0.75mL</td>
<td>1mL</td>
<td>1.25mL</td>
<td>1.5mL</td>
</tr>
</tbody>
</table>

May be further diluted in a compatible fluid

Administer as an intravenous infusion over at least 30 minutes

**Oral**
Disperse one capsule (150mg) in 15mL of water for injection. The resulting oral solution contains clindamycin 10mg/mL.

<table>
<thead>
<tr>
<th>Dose</th>
<th>2.5mg</th>
<th>5mg</th>
<th>7.5mg</th>
<th>10mg</th>
<th>12.5mg</th>
<th>15mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>0.25mL</td>
<td>0.5mL</td>
<td>0.75mL</td>
<td>1mL</td>
<td>1.25mL</td>
<td>1.5mL</td>
</tr>
</tbody>
</table>

Discard any remaining.

**Compatible Fluids**
Glucose 5%, glucose 10%, glucose/sodium chloride solutions, sodium chloride 0.9%

**Adverse Effects**

**Common**
Diarrhoea, vomiting, abdominal pain, rash

**Infrequent**
Clostridium difficile-associated disease

**Rare**
Anaphylaxis, blood dyscrasias, polyarthritis, jaundice, raised liver enzymes, hepatotoxicity

**Intravenous:** hypotension, cardiac arrest (rapid injection), thrombophlebitis

**Monitoring**
- Hepatic function
- Gastrointestinal status
- Full blood count and renal function during prolonged treatment
Practice Points

> Discontinue if severe diarrhoea develops
> Diarrhoea, colitis and pseudomembranous colitis have been reported and may begin up to several weeks after cessation of therapy
> Some brands of clindamycin injection contain benzyl alcohol which has been associated with serious adverse events including “gassing” syndrome in neonates

Document Ownership & History

Developed by: SA Maternal, Neonatal & Gynaecology Community of Practice
Contact: Health.NeoMed@sa.gov.au
Endorsed by: SA Safety and Quality Strategic Governance Committee
Next review due: 15/12/2022
ISBN number: 978-1-74243-886-3
PDS reference: CG282
Policy history:

Is this a new policy (V1)? N
Does this policy amend or update and existing policy? Y
If so, which version? V1.0
Does this policy replace another policy with a different title? N
If so, which policy (title)?

<table>
<thead>
<tr>
<th>Approval Date</th>
<th>Version</th>
<th>Who approved New/Revised Version</th>
<th>Reason for Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>15/12/17</td>
<td>V2.0</td>
<td>SA Safety and Quality Strategic Governance Committee</td>
<td>Formally reviewed in line with 5 year scheduled timeline for review.</td>
</tr>
<tr>
<td>1/11/12</td>
<td>V1.0</td>
<td>SA Safety and Quality Strategic Governance Committee</td>
<td>Original approved version.</td>
</tr>
</tbody>
</table>